EGLN2 and neoplasm: While tumor growth was not altered in untreated mice carrying p53wt/wt HCT116 shScr or shPHD1 tumors, 5-FU treatment reduced tumor volume by 39.5% in p53wt/wt HCT116 shScr, but by 70% in mice carrying a tumor silenced for PHD1 (Fig 3B).